Mornings Bio: Expected first-half net profit in 2026 to decline year over year by 17.66% to 11.62%

Morninglight Biotech announced that it expects net profit attributable to shareholders of the listed company from January 1, 2026 to June 30, 2026 to be between 177 million yuan and 190 million yuan, representing a year-on-year decline of 17.66% to 11.62%; net profit after deducting non-recurring gains and losses is expected to be between 161 million yuan and 174 million yuan, representing a year-on-year decline of 12.72% to 5.68%.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned